Research Article - (2016) Volume 6, Issue 5

Survival Benefit of Intravenous Busulfan (120 mg/M2) and Fludarabine Myeloablative Regimen for Treatment of Myeloid Malignancies

Niparuck P1*, Pukiat S1, Puavilai T1, Ativitavas T2, Chantrathammachart P1, Boonyawat K1, Wacharapomin P1, Angchaisuksiri P1, Chuncharunee S1, Jootar S1, Atichartakarn V1 and Ungkanont A1
1Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Thailand
2Division of Oncology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Thailand
*Corresponding Author: